Cargando…

Predictive models for overall survival in breast cancer patients with a second primary malignancy: a real-world study in Shanghai, China

BACKGROUND: The incidents of second primary malignancy (SPM) is increasing among breast cancer (BC) patients with long-term progression, adversely affecting survival. The purpose of this study was to screen independent overall survival (OS) risk factors and establish nomograms to predict the surviva...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Ling, Chen, Yichen, Li, Xiaopan, Jin, Hua, Shi, Jianwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724326/
https://www.ncbi.nlm.nih.gov/pubmed/36474253
http://dx.doi.org/10.1186/s12905-022-02079-0
_version_ 1784844388895031296
author Yuan, Ling
Chen, Yichen
Li, Xiaopan
Jin, Hua
Shi, Jianwei
author_facet Yuan, Ling
Chen, Yichen
Li, Xiaopan
Jin, Hua
Shi, Jianwei
author_sort Yuan, Ling
collection PubMed
description BACKGROUND: The incidents of second primary malignancy (SPM) is increasing among breast cancer (BC) patients with long-term progression, adversely affecting survival. The purpose of this study was to screen independent overall survival (OS) risk factors and establish nomograms to predict the survival probabilities of BC patients with SPM. METHOD: A total of 163 BC patients with SPM were recruited during 2002–2015 from a total of 50 hospitals in Shanghai, China. Two nomograms to predict survival from primary BC and SPM diagnosis were constructed based on independent factors screened from multivariable analysis. The calibration and discrimination of nomograms were calculated in the training and validation cohorts. RESULTS: The overall survival rates of BC patients with SPM were 88.34%, 64.42% and 54.66% at 5, 10 and 15 years, respectively. Factors of late TNM stage of SPM (HR = 4.68, 95% CI 2.14–10.25), surgery for SPM (HR = 0.60, 95% CI 0.36–1.00), SPM in the colon and rectum (HR = 0.49, 95% CI 0.25–0.98) and thyroid (HR = 0.08, 95% CI 0.01–0.61) independently affected the OS of BC patients with SPM (p < 0.05). In addition, a longer latency (≥ 5 years) was associated with better OS from BC diagnosis (p < 0.001). Older age (≥ 56) was associated with poor OS from SPM diagnosis (p = 0.019). Two nomograms established based on the above factors had better calibration and discrimination. CONCLUSION: The TNM stage of SPM, surgery for SPM, SPM sites, latency and age at BC diagnosis are independent factors for survival and the two nomograms may provide more personalized management for BC patients with SPM. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12905-022-02079-0.
format Online
Article
Text
id pubmed-9724326
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97243262022-12-07 Predictive models for overall survival in breast cancer patients with a second primary malignancy: a real-world study in Shanghai, China Yuan, Ling Chen, Yichen Li, Xiaopan Jin, Hua Shi, Jianwei BMC Womens Health Research BACKGROUND: The incidents of second primary malignancy (SPM) is increasing among breast cancer (BC) patients with long-term progression, adversely affecting survival. The purpose of this study was to screen independent overall survival (OS) risk factors and establish nomograms to predict the survival probabilities of BC patients with SPM. METHOD: A total of 163 BC patients with SPM were recruited during 2002–2015 from a total of 50 hospitals in Shanghai, China. Two nomograms to predict survival from primary BC and SPM diagnosis were constructed based on independent factors screened from multivariable analysis. The calibration and discrimination of nomograms were calculated in the training and validation cohorts. RESULTS: The overall survival rates of BC patients with SPM were 88.34%, 64.42% and 54.66% at 5, 10 and 15 years, respectively. Factors of late TNM stage of SPM (HR = 4.68, 95% CI 2.14–10.25), surgery for SPM (HR = 0.60, 95% CI 0.36–1.00), SPM in the colon and rectum (HR = 0.49, 95% CI 0.25–0.98) and thyroid (HR = 0.08, 95% CI 0.01–0.61) independently affected the OS of BC patients with SPM (p < 0.05). In addition, a longer latency (≥ 5 years) was associated with better OS from BC diagnosis (p < 0.001). Older age (≥ 56) was associated with poor OS from SPM diagnosis (p = 0.019). Two nomograms established based on the above factors had better calibration and discrimination. CONCLUSION: The TNM stage of SPM, surgery for SPM, SPM sites, latency and age at BC diagnosis are independent factors for survival and the two nomograms may provide more personalized management for BC patients with SPM. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12905-022-02079-0. BioMed Central 2022-12-06 /pmc/articles/PMC9724326/ /pubmed/36474253 http://dx.doi.org/10.1186/s12905-022-02079-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yuan, Ling
Chen, Yichen
Li, Xiaopan
Jin, Hua
Shi, Jianwei
Predictive models for overall survival in breast cancer patients with a second primary malignancy: a real-world study in Shanghai, China
title Predictive models for overall survival in breast cancer patients with a second primary malignancy: a real-world study in Shanghai, China
title_full Predictive models for overall survival in breast cancer patients with a second primary malignancy: a real-world study in Shanghai, China
title_fullStr Predictive models for overall survival in breast cancer patients with a second primary malignancy: a real-world study in Shanghai, China
title_full_unstemmed Predictive models for overall survival in breast cancer patients with a second primary malignancy: a real-world study in Shanghai, China
title_short Predictive models for overall survival in breast cancer patients with a second primary malignancy: a real-world study in Shanghai, China
title_sort predictive models for overall survival in breast cancer patients with a second primary malignancy: a real-world study in shanghai, china
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724326/
https://www.ncbi.nlm.nih.gov/pubmed/36474253
http://dx.doi.org/10.1186/s12905-022-02079-0
work_keys_str_mv AT yuanling predictivemodelsforoverallsurvivalinbreastcancerpatientswithasecondprimarymalignancyarealworldstudyinshanghaichina
AT chenyichen predictivemodelsforoverallsurvivalinbreastcancerpatientswithasecondprimarymalignancyarealworldstudyinshanghaichina
AT lixiaopan predictivemodelsforoverallsurvivalinbreastcancerpatientswithasecondprimarymalignancyarealworldstudyinshanghaichina
AT jinhua predictivemodelsforoverallsurvivalinbreastcancerpatientswithasecondprimarymalignancyarealworldstudyinshanghaichina
AT shijianwei predictivemodelsforoverallsurvivalinbreastcancerpatientswithasecondprimarymalignancyarealworldstudyinshanghaichina